Objective: To compare the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of subfoveal neovascular age-related macular degeneration (NV-AMD) patients, that is, those with early, moderate, and late disease, using a comprehensive economic model. Methods: A Markov framework was used to model lifetime movement of a subfoveal NV-AMD cohort through health states based on visual acuity. The model takes a US payer perspective of patients over the age of 65 years. Clinical efficacy was based on published results for the 0.3 mg pegaptanib and usual care groups. Expert interviews were conducted to determine adverse event treatment patterns and vision rehabilitation resource use. Incidence and costs of comorbidities such as depression and fractures associated with the effects of declining visual acuity were based on our previously published analysis of Medicare data. Transition probabilities were derived from published clinical trial data for each 3-month cycle. Utilities were derived from published sources. Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. Costs and outcomes were discounted 3.0% per annum. Results: Incremental costs per vision-year gained and per quality-adjusted life-year (QALY) gained for early NV-AMD patients were approximately one-third those of patients with late disease ($15,279 vs. $57,230 and $36,282 vs. $132,381, respectively). On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later. Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust. Conclusions: For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.
Introduction
Neovascular age-related macular degeneration (NV-AMD) is a progressive, rapidly developing disease leading to central vision loss and eventually to blindness. Population-based studies across developed countries have estimated the prevalence rate of advanced age-related macular degeneration (AMD), either AMD with geographic atrophy or NV-AMD, to be between 1.7 and 1.9 per 100 individuals [1] . By the year 2020, almost 3 million individuals will suffer from NV-AMD or geographic atrophy in the United States alone [2] . The resulting visual impairment affects patient quality of life as much as arthritis, asthma, diabetes, and stroke [3] . The economic burden of AMD is high because people with impaired vision may experience an increased risk of falls and fractures [4] [5] [6] , depression [7, 8] , and the need for daily support services or nursing home care [9] . In the United States, the yearly economic loss to the gross domestic product from NV-AMD-related sequelae has been estimated to be $2.866 billion for those aged 65 years and older and $2.530 billion for individuals younger than 65 years [10] .
The functional abilities of AMD patients and the cost-effectiveness of AMD treatments have been found to vary according to visual acuity level. For example, AMD patients with early disease (visual acuity better than 20/80) reported a significantly lower quality of life than those without AMD, and consistent trends toward worse quality of life were demonstrated as visual acuity progressed toward blindness [11] . Using the time trade-off method of utility analysis, those with clinically severe AMD were found to have, on average, a significantly worse self-perceived health-related quality of life than those with milder AMD [12] . Severity of AMD also has been shown to be associated with lower scores on the Activities of Daily Vision Scale, particularly for near vision and driving [13] . A costeffectiveness assessment [14] considered the treatment benefit of photodynamic therapy with verteporfin (PDT) for NV-AMD patients. PDT therapy, which is indicated only for predominantly classic lesions, involves injection of verteporfin through a vein in the hand or arm; the drug circulates through the body and attaches to abnormal vessels beneath the macula; verteporfin is activated by a laser shone into the back of the eye leading to closure of abnormal blood vessels and stoppage of leaking of fluid and blood beneath the retina. Using two baseline vision thresholds, 20/40 and 20/200, the authors found treatment to be less costeffective in NV-AMD patients with lower visual acuities; PDT for a patient with 20/40 vision in the better-seeing eye would cost an insurer $86,721 to obtain one quality-adjusted life-year (QALY) versus $173,984 per QALY for a patient with 20/200 vision in the better-seeing eye [14] .
In the current health-care environment, it is important to allocate limited resources to their most efficient use to maximize health and cost benefits. This approach includes not only the selection of but also the timing of therapeutic interventions. This report addresses the use and timing of pegaptanib sodium (Macugen) in the treatment of NV-AMD. By way of review, pegaptanib is a selective inhibitor of the 165 isoform of vascular endothelial growth factor (VEGF) and is indicated for all subtypes of NV-AMD [15] . It has been suggested that early treatment of NV-AMD with pegaptanib may limit choroidal neovascularization (CNV)-induced damage to photoreceptors and/or the retinal pigment epithelium and so be associated with better vision results. An exploratory analysis of data from the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) [16] trial found that early detection and treatment with pegaptanib in subjects with early NV-AMD resulted in superior vision outcomes. For example, in patients with early disease defined as occult with no classic CNV, absence of lipid, and better baseline visual acuity in the fellow eye, the week-54 responder rate was 80% (24/30) among those treated with 0.3 mg pegaptanib versus 57% (20/35) in the usual care group (P = 0.05). Thus, early treatment may lead to reduced resource use as patient functionality is maintained, along with measurable preservation in patient quality of life.
In order to better understand the implications of these clinical studies, we developed a comprehensive economic model comparing the cost-effectiveness of pegaptanib and usual care within three distinct cohorts of NV-AMD patients, that is, those with early, moderate, and late disease.
Materials and Methods

Model Scope
A Markov framework was used to model the lifetime movement of an NV-AMD cohort through five health states based on visual acuity in the better-seeing eye (Fig. 1) . This approach was first developed in ophthalmology to assess the treatment of diabetic eye disease [17] . Visual acuity in the better-seeing eye was used because previous studies have shown that costs [18] and quality of life [19] are highly correlated with visual acuity in that eye. The model's structure was validated through interviews with clinical experts and accounted for different time horizons (cycle time: 3 months; base case: lifetime), distributions of patient age and sex, lesion subtypes, and starting visual acuity levels. The model takes a US payer perspective and does not consider either indirect costs or patient out-of-pocket expenses. The perspective was that of a typical cost utility analysis where costs to the payer are assessed against utility benefits to the patient. Because NV-AMD primarily affects the elderly [20] [21] [22] [23] , this analysis is restricted to those age 65 years and older. Comparators were pegaptanib and usual care based on the results of a 2-year clinical study, the V.I.S.I.O.N. trial [15, 24, 25] .
V.I.S.I.O.N.Trial
Two pivotal phase 2/3 multicenter, randomized, double-masked trials [15, 24, 25] in patients with all subtypes of NV-AMD were performed. Intravitreal pegaptanib (0.3 mg, 1 mg, or 3 mg) or sham injection was administered every 6 weeks for 54 weeks. At week 54, those assigned to pegaptanib were rerandomized to continue or discontinue treatment for 48 additional weeks (8 injections); patients assigned to usual care (sham) in year 1 were rerandomized to continue or discontinue usual care or to receive one of the three pegaptanib doses. At the time of the V.I.S.I.O.N. trial, PDT was the only treatment indicated for patients with NV-AMD, and the trial design allowed the use of PDT in both the experimental and the usual care arms at the discretion of the physician. In all, 1186 subjects were included in year-1 efficacy analyses. In the 0.3 mg (approved dose) group, 70% of subjects lost <3 lines of visual acuity (were responders) compared to 55% of those receiving usual care (P < 0.001); severe vision loss (6 lines) was half as frequent in the pegaptanib compared to usual care groups occurring in 10% and 22% of subjects, respectively (P < 0.001). In year 2, 1053 patients were rerandomized, and 941 were evaluated at week 102. Ongoing visual benefit was seen in subjects who received pegaptanib continuously compared to 2 years of usual care or pegaptanib cessation. Loss of <3 lines from baseline between weeks 54 and 102 was seen in 7% of subjects who continued pegaptanib, compared to 14% of those who either discontinued pegaptanib or remained on usual care. Over 2 years, pegaptanib was well tolerated, and most ocular adverse events were transient, mild to moderate in intensity, and related to the injection. Endophthalmitis occurred at a rate of 0.16% per injection in year 1, and 9/12 subjects who developed endophthalmitis remained in the trial. No case of endophthalmitis was reported in year 2.
Input Parameters
Patient parameters. Distributions of patients by age and sex groupings were based on the US population [26] . Patient ages were grouped as 65 to 74 years and more than 74 years; the model scenario reported herein included patients aged 65 years or older.
The annual incidence of advanced AMD, defined as either NV-AMD or AMD with geographic atrophy, by age and sex group was estimated based on the 10-year incidence data [27] . The model considered only patients with subfoveal NV-AMD because pegaptanib and PDT have prescribing patterns that overlap in these patients. To specifically model a population with subfoveal NV-AMD, the number of patients in each age and sex group was derived by multiplying the ageand sex-specific annual incidence rate of advanced AMD by 69.47% (NV-AMD) [2] . We then narrowed the NV-AMD population by extracting only those with subfoveal disease or 78.50% of the NV-AMD subjects [28] . The model included patients with all subtypes of subfoveal NV-AMD: predominantly classic CNV (area of entire lesion was 50% classic; 20.00% of patients), minimally classic CNV (area of classic component was <50% of the entire lesion; 7.00%), and occult with no classic CNV (73.00%) [28] .
Three runs of the model were conducted with cohorts of newly diagnosed patients. Patients were classified as having early, moderate, or late subfoveal NV-AMD defined as visual acuity in the better-seeing eye of 20/40 to more than 20/80, 20/80 to more than 20/200, and 20/200 to more than 20/400, respectively. The initial distribution of patients within these visual acuity ranges was obtained from the baseline visual acuity distribution of all patients in the V.I.S.I.O.N. trial (early, 36.05%; moderate, 46.05%; late, 17.06%) [15] . All patients were assumed to have bilateral disease.
Age-and sex-specific all-cause mortality rates were derived from US Vital Statistics Reports [29] . Specifically, all-cause mortality by 10-year age groups was obtained. Mortality rates for each patient age were then projected by fitting curves to these data. An analysis of Medicare claims data showed that patients who are blind (visual acuity: 20/200) have a relative risk of death of 1.5 compared to patients who are not blind [30] . In the model, mortality rates were derived by applying a relative risk of 1.5 to the age-and sexspecific mortality rates for the US population to the 20/200 to more than 20/400 visual acuity state. For all model states, mortality rates increased as patients aged in the model.
Clinical efficacy and safety parameters.
Clinical efficacy measured by visual acuity was based on V.I.S.I.O.N. trial [15, 24] results for the 0.3 mg pegaptanib group and for those receiving usual care. Threemonth transition probabilities for the first and second years of treatment were estimated using the firstand second-year cumulative clinical probabilities for pegaptanib or usual care in terms of loss or gain in lines of visual acuity (Table 1) Clinical experts were interviewed to identify potentially clinically significant adverse events for the model. Six experts reviewed the list of adverse events reported during the V.I.S.I.O.N. trial [15, 25] and identified those events considered to be most important clinically and most likely to substantially impact costs. Three adverse events were included in the model, and their annual rates of occurrence were obtained from the V.I.S.I.O.N. trial [15, 25] : endophthalmitis, 1.35%; traumatic injury to lens, 0.56%; and retinal detachment, 0.67%. The model assumed that adverse event rates were independent of lesion subtype and visual acuity states.
Utilities. Utility values ranged from 0.0 to 1.0, where 1.0 represented perfect health and 0.0 represented death. Like previous AMD models [14, 31] , utility values for the visual acuity states were obtained from a study by Brown et al. [32] in which utilities for AMD patients were measured empirically using time tradeoff and standard gamble methods. The visual acuity ranges used by Brown et al. [32] were mapped as closely as possible to the thresholds measured in clinical trials (Table 2) .
Resource Use and Cost Parameters
The average number of outpatient appointments for patients treated with pegaptanib was assumed to be equal to the average number of pegaptanib treatments per year. Thus, patients were assumed to have 8.4 and 6.9 outpatient appointments and drug administrations in years 1 and 2, respectively. The average unit cost of an outpatient appointment, pegaptanib procedure, and pegaptanib were estimated at $65.18, $202.75, and $1054.70, respectively [33, 34] . We also assumed that pegaptanib treatment did not require any additional rounds of fluorescein angiography or optical coherence tomography, because those modalities are specifically not part of the recommended indications for pegaptanib administration. The model assumed that patients in the usual care arm received either PDT or no treatment. The cost of PDT and an administration of PDT within 1 year was estimated at $1341.90 and $323.64. Percentages of patients receiving PDT and average number of treatments in years 1 and 2 were based on findings of the V.I.S.I.O.N. trial [15, 24] (Table 3) . Total annual costs of primary and concomitant therapies are presented in Table 3 . Drug and procedure costs were based on unit costs from US published sources, including Medicare Part B Drugs Average Sales Prices [33] and the Resource-Based Relative Value Scale (RBRVS) [34] based on their respective Current Procedural Terminology (CPT) codes. The model assumed as a default that treatment ceased if visual acuity dropped below 20/400.
To estimate the economic impact of these treatment-related adverse events (e.g., endophthalmitis, traumatic injury to lens, and retinal detachment), interviews with six clinical experts were performed. Specifically, the clinical experts estimated the percentage of patients who would be treated for each adverse event and specified treatment patterns for those patients. Unit costs for resources were obtained from the RBRVS based on their respective CPT codes (Table 4) [34] . Modeled costs for treating adverse events accounted for PDT-related adverse events among patients who received PDT in addition to pegaptanib or usual care. Long-term clinical consequences such as potential reduction in vision were assumed to be considered in the clinical efficacy as seen in the trial.
Patients with low vision, in particular those with AMD, suffer from numerous comorbidities and frequently require assistance with activities of daily living. A recent analysis of US Medicare data demonstrated that people with impaired vision are at greater risk than the general population of depression, injuries such as fractures, and the need for skilled nursing facility or nursing home care [18] . The model allowed patients with varying degrees of visual acuity to use resources at varying rates and to incur varying costs. Table 2 Utilities for patients with age-related macular degeneration using visual acuity in the better-seeing eye Specifically, average annual noneye-related care costs were extracted from Javitt et al. [18] by vision acuity (Table 5) . These costs were then inflated to 2006 dollars using the medical consumer price index [35] .
Costs and odds ratios are presented in Table 6 . The model assumed that the cost of nursing home care was independent of visual acuity; the average cost of a semiprivate nursing home room in the United States was included in the model [36] . The model also accounted for resource use and costs for low-vision rehabilitation and vision aids; inputs were based on interviews with clinical experts.
Transition Probabilities
Transitions between visual acuity levels were based on a Ն3-line gain, no progression (defined as <3-line loss), a 3-to 6-line loss, and a Ն6-line loss on the visual acuity scale as seen in the V.I.S.I.O.N. trial [15, 24, 25] . Specifically, 3-month transition probabilities for the first and second years were estimated from clinical efficacy results of years 1 and 2 (Table 1 ). In year 3 and beyond after treatment is discontinued, patients in both the pegaptanib and usual care cohorts were assumed to progress through the model according to transition probabilities as estimated for year 2 in the usual care cohort. As some efficacy may be thought to remain after treatment discontinuation, sensitivity analysis was performed to examine the impact of improved efficacy over usual care in year 3 and beyond. Transitioning between health states was adjusted to be applicable among patients who did not die in each 3-month period. Efficacy by lesion subtype also was considered within the model. Nevertheless, because pegaptanib was shown to be equally efficacious in all lesion subtypes, transitioning between visual acuity health states was similar for all lesion subtypes [15, 24] .
Model Outcomes
To evaluate the clinical and economic benefits of treating patients earlier in the disease state, lifetime visionyears, QALYs, lifetime total costs per patient, and incremental costs per vision-year and QALYs gained are reported for pegaptanib and usual care stratified by disease severity (early, moderate, and late subfoveal NV-AMD). Costs are reported in 2006 US dollars. Costs and outcomes were discounted at 3% per annum.
Sensitivity Analyses
Several one-way sensitivity analyses were performed to test the impact of various assumptions in the model on the robustness of the results. The following parameters were varied in the sensitivity analyses: cost and utility values for each model state; clinical efficacy after 1 and 2 years of treatment; probability of adverse events; risk of death due to blindness; and rate of treatment efficacy after 2 years. Clinical efficacy was changed by varying the primary clinical end point (not losing more than 15 letters) by Ϯ30%. All transition probabilities were changed proportionately. Utility values were at the lower 95% confidence limit (lower bound) and at the upper 95% confidence limit (upper bound). 
Results
Gains with pegaptanib were seen in all three patient cohorts but were most pronounced in patients receiving early care. Early treatment with pegaptanib provided substantial gains in both vision-years and QALYs ( Table 7) . The largest gains in vision-years and QALYs occurred in early subfoveal NV-AMD patients treated with pegaptanib ( Fig. 2) . For example, compared with usual care, patients with early disease treated with pegaptanib gained 0.75 more vision-years and 0.32 more QALYs compared to 0.22 more visionyears and 0.09 more QALYs, respectively, for patients with more severe vision. In addition to the clinical benefit to patients, an economic benefit for payers was observed. On average, patients treated early with either pegaptanib or usual care incurred lower lifetime total direct costs than those treated later ( 
Sensitivity Analysis
Sensitivity analysis showed that base-case incremental costs per QALY gained for pegaptanib versus usual care were relatively robust to changes in all parameters examined in patients with early and moderate sub- foveal NV-AMD (Figs. 4 and 5) . In these patients, results were sensitive to changes in clinical efficacy both at 1 and 2 years and in patient utility of more severe vision health states. Changes in clinical efficacy in year 1 only resulted in being the second most sensitive parameter in patients with early disease. Nevertheless, changes in results were not that variable. In patients with late disease, similar sensitivity in parameters occurred (Fig. 6 ). Nevertheless, changes in clinical efficacy at both 1 and 2 years and patient utility and costs of more severe vision health states seemed to have a larger impact on the incremental cost per QALY gained. The model was not sensitive to ranges of combined probabilities of adverse events, costs, and utilities in less severe vision health states, and discount rates normally accepted in cost-effectiveness models (data not shown).
In addition to the above sensitivity analyses, we ran a worst-case scenario under which pegaptanib may perform. In this analysis, pegaptanib clinical benefit at both years 1 and 2 was decreased by 30%, no clinical benefit in years 3+ occurred, and the probability of pegaptanib-related adverse events was increased by 30%. For patients with early, moderate, and late NV-AMD, the incremental cost per QALY was $82,996, $96,122, and $185,415, respectively.
Discussion
Previous research conducted in the United States has demonstrated that pegaptanib is more cost-effective overall than either no treatment [37] or treatment with PDT and verteporfin [38] . Results of the current study suggest that early treatment with pegaptanib offers both direct medical benefit to patients and economic benefit to payers. Early treatment improves costeffectiveness of care compared to waiting until visual acuity worsens. Our study suggests that early treatment also reduces lifetime total direct costs of care. Incremental cost-effectiveness ratios for pegaptanib compared to usual care are more favorable throughout all three stages of subfoveal NV-AMD, but the greatest incremental benefits were seen in those treated early.
The actual cost-effectiveness of early pegaptanib treatment may be more attractive than reflected by the model because pegaptanib's broad indication and mechanism of action may reduce the complexity of the clinical treatment pathway. For example, the decision to re-treat with pegaptanib every 6 weeks is not predicated on findings of fluorescein angiography. Therefore, personnel time and costs associated with such diagnostic testing may be avoided. In addition, patient flow may be facilitated by the fact that those receiving pegaptanib do not require lengthy post-treatment observation in the clinician's office. The cost-effectiveness of early treatment with pegaptanib parallels findings of a subanalysis of V.I.S.I.O.N. trial [16] data that explored visual acuity outcomes in patients with early disease. In general, pegaptanib treatment of patients with early NV-AMD resulted in superior vision-related outcomes compared to outcomes for the overall population of pegaptanibtreated patients. Moreover, pegaptanib treatment was associated with better outcomes than usual care among patients with early disease. Thus, responder rates (loss of <15 letters of visual acuity) were significantly higher among pegaptanib-treated patients while those receiving usual care lost significantly more letters and were more likely to have severe vision loss than patients treated with pegaptanib [16] .
One would ideally like to compare our findings to those of previous economic analyses [14, [39] [40] [41] . Nevertheless, such comparison is hindered by heterogeneity with regard to lesion types studied, model time horizons, health states analyzed, vision loss-related costs included, and use of the better or worse eye or both. Although lifetime model time horizons are recommended to ensure that long-term health and cost benefits of treatment are captured [42] , the only economic analysis of PDT to use a lifetime model was conducted by Sharma et al. [14] . Their Markov model Bandello's model with the one offered here. In addition, the data used to populate Bandello's model are based on 1-year efficacy data for the three comparators, while we utilize 2 years of clinical efficacy data to extrapolate more precisely the lifetime impact of treatment.
Our study differs in two important respects from prior reports. Unlike previous models, our model fully considered the entire spectrum of NV-AMD subtypes, all direct costs, and the natural progression of the disease over a lifetime. The model thus provides more accurate estimates of the cost-effectiveness of AMD treatments than previous models. Second, the structure, assumptions, and input parameters of the model were validated by an outside panel of clinical experts.
Like all modeling exercises, our study has several limitations. First, we were not able to include indirect costs for missed work and caregiver burden because of lack of data. Including such parameters and taking a US societal rather than a US payer perspective would certainly lead to more favorable incremental costeffectiveness ratios for pegaptanib versus usual care because patients receiving pegaptanib would likely miss fewer days of work and require less assistance with activities of daily living than those receiving usual
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Minimum Plausible Value Figure 6 Sensitivity of parameter variation on incremental cost per quality-adjusted life-year (QALY) gained: pegaptanib versus usual care, late subfoveal neovascular age-related macular degeneration (20/200 to >20/400 visual acuity). *Clinical efficacy is changed by varying the primary clinical end point (not losing more than 15 letters) by Ϯ30%. All transition probabilities were changed proportionately. **Utility values are at the lower 95% confidence limit (lower bound: LB) and at the upper 95% confidence limit (upper bound: UB). RR, relative risk.
care. Second, utility decrements were not assigned to adverse events because no reliable source of such decrements could be found. Nevertheless, the known adverse events experienced by patients receiving pegaptanib were both mild and infrequent. It is not likely that the results would be substantially affected if utility decrements for adverse events were included. A model developed by Brown et al. [40] did include utility decrements for adverse events and the total effect was only 0.002 QALYs. Third, although the model used pegaptanib as the sole comparator to usual care, two other VEGF inhibitors, ranibizumab and bevacizumab, also are being used to treat NV-AMD; future models should assess the cost-effectiveness of these therapies as well. Fourth, utility estimates were based on vision in the better-seeing eye; it would be useful, but considerably more complex, to consider bilateral visual acuity. Finally, after year 2, model efficacy rates were based on usual care rather than assuming an ongoing benefit of pegaptanib, a deliberately pessimistic assumption that may underestimate the true potential treatment benefits of pegaptanib.
In conclusion, our study suggests that early treatment with pegaptanib to optimize clinical outcomes is more cost-effective from a US payer perspective than waiting for the onset of advanced or late disease. For patients with subfoveal NV-AMD, treatment with pegaptanib should be started as early as possible to maximize the clinical and economic benefits.
